Psoriatik artritin tedavisinde yeni ilaçların karşılaştırması

Figen Yargucu Zihni

doi:10.19161/etd.648990

Diğer

The comparison of new biologic treatments in psoriatic arthritis

Yıl 2019, , 48 - 50, 25.10.2019

Figen Yargucu Zihni

https://doi.org/10.19161/etd.648990

Öz

Psoriatic arthritis (PsA) is characterized by a wide spectrum of articular and extra-articular clinical manifestations including peripheral arthritis, spondylitis, enthesitis, dactylitis, skin and eye involvement, and systemic features such as metabolic syndrome and cardiovascular ischemic disease. The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. Given the heterogeneity PsA, the treatments should be tailored to individual cases

Anahtar Kelimeler

Psoriatic arthritis, biologicals

Kaynakça

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17.
Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42(12):1460-8.
Lloyd P, Ryan C, Menter A. Psoriatic arhtitis: an update. Arthritis 2012;2012:1762982.
Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl 2012;89:32-5.
Dougados M, Baeten D. Spondyloarthritis. Lancet 2011(9783);377:2127–37.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.
Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013;149:1180-5.
Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol 2016;68(5):1060-71.
Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499510.
Kristianslund EK, Fagerli KM, Lie E, et al. Real life effectiveness of TNF inhibitors in psoriatic arthritis: Are changing national policies on choice of TNF inhibitör reflected in response to treatment? EULAR 2017 FRI0490 Ann Rheum Dis 2017;76(Suppl 2):673-4.
Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 2014, 26:361-70.
Jørgensen TS, Dreyer L, Gudbjornsson B, et al. Prescription patterns of tumor necrosis factor inhibitör and ustekinumab in psoriatic arthritis: A Nordic population-based cohort study. EULAR 2017 FRI0518 Ann Rheum Dis 2017;76(Suppl 2):686.
Kawalec P, Holko P, Moćko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int 2018 Feb;38(2):189-201.
Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol 2016;12:743-50.
Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) 2013;52:1754-7.
Cantini F, Niccoli L, Nannini C, et al. Semin Arthritis Rheum 2017;47(2):183-92.
Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors inpsoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72(11):1840-4.
Biggioggero M, Favalli EG. 10-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 2014;75(Suppl 1):S38–S41.
Ungprasert P, Thongprayoon C, Davis JM 3rd. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol 2016 Jul;35(7):1795-803.
Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int 2016 May;36(5):603-12.
Griffiths CE, Strober BE, van de Kerkhof P, et al; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28.
Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014;371(4):326-38.
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386(9993):541-51.
Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 2018 Jun 13. pii: S00490172(18)30150-1.
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73(3):400-9.
Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 2017;47(2):183-92.